| Literature DB >> 24862638 |
Mary Eapen1, Paul O'Donnell2, Claudio G Brunstein3, Juan Wu4, Kate Barowski4, Adam Mendizabal4, Ephraim J Fuchs5.
Abstract
Two parallel phase II trials in adults with hematologic malignancies demonstrated comparable survival after reduced-intensity conditioning and transplantation of either 2 HLA-mismatched umbilical cord blood (UCB) units or bone marrow from HLA-haploidentical relatives. Donor choice is often subject to physician practice and institutional preference. Despite clear preliminary evidence of equipoise between HLA-haploidentical related donor and double unrelated donor UCB transplantation, the actual prospect of being randomized between these 2 very different donor sources is daunting to patients and their treating physicians alike. Under these circumstances, it is challenging to conduct a phase III randomized trial in which patients are assigned to the UCB or haploidentical bone marrow arms. Therefore, we aimed to provide an evidence-based review and recommendations for selecting donors for adults without an HLA-matched sibling or an HLA-matched adult unrelated donor.Entities:
Keywords: Alternative donor transplantation; Donor selection algorithm; Hematologic malignancy
Mesh:
Substances:
Year: 2014 PMID: 24862638 PMCID: PMC4163123 DOI: 10.1016/j.bbmt.2014.05.015
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742